High Lipoprotein(a) Levels are Associated With Long-Term Adverse Outcomes in Acute Myocardial Infarction Patients in High Killip Classes |
Cho, Jae-Yeong
(Heart Research Center of Chonnam National University Hospital, Cardiovascular Research Institute of Chonnam National University)
Jeong, Myung-Ho (Heart Research Center of Chonnam National University Hospital, Cardiovascular Research Institute of Chonnam National University) Ahn, Young-Keun (Heart Research Center of Chonnam National University Hospital, Cardiovascular Research Institute of Chonnam National University) Hong, Young-Joon (Heart Research Center of Chonnam National University Hospital, Cardiovascular Research Institute of Chonnam National University) Park, Hyung-Wook (Heart Research Center of Chonnam National University Hospital, Cardiovascular Research Institute of Chonnam National University) Yoon, Nam-Sik (Heart Research Center of Chonnam National University Hospital, Cardiovascular Research Institute of Chonnam National University) Yoon, Hyun-Ju (Heart Research Center of Chonnam National University Hospital, Cardiovascular Research Institute of Chonnam National University) Kim, Kye-Hun (Heart Research Center of Chonnam National University Hospital, Cardiovascular Research Institute of Chonnam National University) Kim, Ju-Han (Heart Research Center of Chonnam National University Hospital, Cardiovascular Research Institute of Chonnam National University) Cho, Jeong-Gwan (Heart Research Center of Chonnam National University Hospital, Cardiovascular Research Institute of Chonnam National University) Park, Jong-Chun (Heart Research Center of Chonnam National University Hospital, Cardiovascular Research Institute of Chonnam National University) Kang, Jung-Chaee (Heart Research Center of Chonnam National University Hospital, Cardiovascular Research Institute of Chonnam National University) |
1 | Jurgens G, Taddei-Peters WC, Koltringer P, et al. Lipoprotein (a) serum concentration and apolipoprotein (a) phenotype correlate with severity and presence of ischemic cerebrovascular disease. Stroke 1995;26:1841-8. DOI ScienceOn |
2 | Morishita R, Ishii J, Kusumi Y, et al. Association of serum oxidized lipoprotein (a) concentration with coronary artery disease: potential role of oxidized lipoprotein (a) in the vascular wall. J Atheroscler Thromb 2009;16:410-8. DOI ScienceOn |
3 | Maher VM, Brown BG, Marcovina SM, Hillger LA, Zhao XQ, Albers JJ. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein (a). JAMA 1995;274:1771-4. DOI ScienceOn |
4 | Kastelein JJ, Wedel MK, Baker BF, et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 2006;114:1729-35. DOI ScienceOn |
5 | Heinemann K, Rubig A, Strothmann A, Nahum GG, Heinemann LA. Prevalence and opinions of hormone therapy prior to the Women's Health Initiative: a multinational survey on four continents. J Womens Health 2008;17:1151-66. DOI ScienceOn |
6 | Ribichini F, Steffenino G, Dellavalle A, et al. Plasma lipoprotein (a) is not a predictor for restenosis after elective high-pressure coronary stenting. Circulation 1998;98:1172-7. DOI ScienceOn |
7 | Rhew JY, Jeong MH, Hong YJ, et al. The effects of lipoprotein (a) on coronary stent restenosis. Korean Circ J 2001;31:476-83. DOI |
8 | Hoffmann R, Minz GS, Dussaillant GR, et al. Patterns and mechanisms of in-stent restenosis: a serial intravascular ultrasound study. Circulation 1996;94:1247-54. DOI ScienceOn |
9 | Grainger DJ, Kirschenlohr HL, Metcalfe JC, Weissberg PL, Wade DP, Lawn RM. Proliferation of human smooth muscle cells promoted by lipoprotein (a). Science 1993;260:1655-8. DOI |
10 | Morita Y, Himeno H, Yakuwa H, Usui T. Serum lipoprotein (a) level and clinical coronary tenosis progression in patients with myocardial infarction: re-revascularization rate is high in patients with high-Lp(a). Circ J 2006;70:156-62. DOI ScienceOn |
11 | Sim DS, Kim JH, Jeong MH. Differences in clinical outcomes between patients with ST-elevation versus non-ST-elevation acute myocardial infarction in Korea. Korean Circ J 2009;39:297-303. DOI ScienceOn |
12 | Marcovina SM, Albers JJ, Scanu AM, et al. Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein (a). Clin Chem 2000;46:1956-67. |
13 | Kim CJ, Kwak MH, Kim KM, Ryu WS, Park JT, Ryoo UH. Lipoprotein (a) as an acute phase reactant. Korean J Lipidol 1996;6:111-5. |
14 | Kostner GM, Gavish D, Leopold B, Bolzano K, Weintraub MS, Breslow JL. HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation 1989;80:1313-9. DOI ScienceOn |
15 | Hearn JA, Donohue BC, Baalbaki H, et al. Usefulness of serum lipoprotein (a) as a predictor of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1992;69:736-9. DOI ScienceOn |
16 | Marcovina SM, Koschinsky ML, Albers JJ, Skarlatos S. Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein (a) and Cardiovascular Disease: recent advances and future directions. Clin Chem 2003;49:1785-96. DOI ScienceOn |
17 | Insull W Jr, McGovern ME, Schrott H, et al. Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis. Arch Intern Med 2004;164:1121-7. DOI ScienceOn |
18 | Merki E, Graham MJ, Mullick AE, et al. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein (a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein (a) transgenic mice. Circulation 2008;118:743-53. DOI ScienceOn |
19 | Desmarais RL, Sarembock IJ, Ayers CR, Velmon SM, Powers ER, Gimple LW. Elevated serum lipoprotein (a) is a risk factor for clinical recurrence after coronary balloon angioplasty. Circulation 1995;91:1403-9. DOI ScienceOn |
20 | Park SH, Shin GJ. Lipoprotein (a) as a risk factor for coronary heart disease: whether related with NIDDM or not. Korean Circ J 1996;26:507-13. DOI |
21 | Danesh J, Collins R, Peto R. Lipoprotein (a) and coronary heart disease: meta-analysis of prospective studies. Circulation 2000;102:1082-5. DOI ScienceOn |
22 | Seman LJ, Breckenridge WC. Isolation and partial characterization of apolipoprotein (a) from human lipoprotein (a). Biochem Cell Biol 1986;64:999-1009. DOI ScienceOn |
23 | Kamstrup PR, Benn M, Tybjaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein (a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation 2008;117:176-84. DOI ScienceOn |
24 | Foody JM, Milberg JA, Pearce GL, Sprecher DL. Lipoprotein (a) associated with coronary artery disease in older women: age and gender analysis. Atherosclerosis 2000;153:445-51. DOI ScienceOn |
25 | Jenner JL, Ordovas JM, Lamonfava S, et al. Effects of age, sex, and menopausal status on plasma lipoprotein (A) levels: the Framingham Offspring Study. Circulation 1993;87:1135-41. DOI ScienceOn |
26 | Carlson LA, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipemic subjects treated with nicotinic-acid. J Intern Med 1989;226:271-6. DOI ScienceOn |
27 | Harpel PC, Chang VT, Borth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein (a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. Proc Natl Acd Sci U S A 1992;89:10193-7. DOI ScienceOn |
28 | Lee CK. Lipoprotein(a), Lp(a). Korean Circ J 1993;23:631-3. DOI |
29 | Hajjar KA, Gavish D, Breslow JL, Nachman RL. Lipoprotein (a) modulation of endothelial surface fibrinolysis and its potential role in atherosclerosis. Nature 1989;339:303-5. DOI ScienceOn |
30 | Harpel PC, Gordon BR, Parker TS. Plasmin catalyzes binding of lipoprotein (a) to immobilized fibrinogen and fibrin. Proc Natl Acd Sci U S A 1989;86:3847-51. DOI ScienceOn |